CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 100.0%

Compliant submissions 1

Incompliant submissions 0

Total trials 1

My Organizations' Clinical Trials

Showing 200 of 279 entries

View as:

A Study of FMT in Patients With AML Allo HSCT in Recipients

Phase: N/A Priority: Normal

NCT ID: NCT03678493 Org: User:

Start: 09/09/19 End: 12/04/23 Due: 12/04/24

Stem Cell Transplant for Immunologic or Histiocytic Disorders

Phase: N/A Priority: Normal

NCT ID: NCT00176865 Org: User:

Start: 08/31/02 End: 08/31/14 Due: 08/31/15

EMR Chemotoxicity Risk Calculator To Decrease Chemotherapy Toxicity

Phase: N/A Priority: Normal

NCT ID: NCT05809557 Org: User:

Start: 01/09/23 End: 01/09/24 Due: 01/09/25

Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy

Phase: N/A Priority: Normal

NCT ID: NCT01601548 Org: User:

Start: 07/31/12 End: 07/31/13 Due: 07/31/14

Clinical Trial of Two Study Drinks in Detoxification of Environmental Toxicants and Carcinogens

Phase: N/A Priority: Normal

NCT ID: NCT03978117 Org: User:

Start: 02/18/21 End: 11/13/24 Due: 11/13/25

Stem Cell Transplantation for Hurler

Phase: N/A Priority: Normal

NCT ID: NCT00176917 Org: User:

Start: 05/31/99 End: 05/31/10 Due: 05/31/11

Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS

Phase: N/A Priority: Normal

NCT ID: NCT03417154 Org: User:

Start: 08/13/18 End: 01/25/22 Due: 01/25/23

Early Diagnosis Of Childhood Cerebral ALD

Phase: N/A Priority: Normal

NCT ID: NCT02948062 Org: User:

Start: 11/30/18 End: 07/31/23 Due: 07/31/24

Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Phase: N/A Priority: Normal

NCT ID: NCT00725062 Org: User:

Start: 06/30/08 End: 04/30/10 Due: 04/30/11

Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia

Phase: N/A Priority: Normal

NCT ID: NCT00167167 Org: User:

Start: 12/31/95 End: 01/31/06 Due: 01/31/07

High Dose Chemotherapy and Autologous Transplant for Neuroblastoma

Phase: N/A Priority: Normal

NCT ID: NCT01526603 Org: User:

Start: 03/28/12 End: 05/30/23 Due: 05/30/24

Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis

Phase: N/A Priority: Normal

NCT ID: NCT00618540 Org: User:

Start: 01/31/07 End: 05/31/13 Due: 05/31/14

Allo HSCT Using RIC for Hematological Diseases

Phase: N/A Priority: Normal

NCT ID: NCT02661035 Org: User:

Start: 03/09/17 End: 05/29/23 Due: 05/29/24

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00748163 Org: User:

Start: 08/31/08 End: 08/31/08 Due: 08/31/09

Biomarker Feedback for Smoking Cessation

Phase: N/A Priority: Normal

NCT ID: NCT02206971 Org: User:

Start: 05/31/12 End: 12/31/14 Due: 12/31/15

Gut Microbiota in Intestinal Barrier Damage in Acute Leukemia Patients Undergoing Inpatient Induction

Phase: N/A Priority: Normal

NCT ID: NCT03316456 Org: User:

Start: 08/22/17 End: 04/01/19 Due: 04/01/20

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Phase: N/A Priority: Normal

NCT ID: NCT03642626 Org: User:

Start: 12/18/18 End: 06/01/28 Due: 06/01/29

Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa

Phase: N/A Priority: Normal

NCT ID: NCT00478244 Org: User:

Start: 04/30/07 End: 08/31/11 Due: 08/31/12

Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca

Phase: N/A Priority: Normal

NCT ID: NCT00784524 Org: User:

Start: 09/30/08 End: 07/31/14 Due: 07/31/15

Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal

NCT ID: NCT00882206 Org: User:

Start: 04/30/09 End: 01/31/13 Due: 01/31/14

Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL

Phase: N/A Priority: Normal

NCT ID: NCT03019666 Org: User:

Start: 10/18/17 End: 08/15/22 Due: 08/15/23

Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)

Phase: N/A Priority: Normal

NCT ID: NCT05705700 Org: User:

Start: 02/28/23 End: 01/31/30 Due: 01/31/31

Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor

Phase: N/A Priority: Normal

NCT ID: NCT01171469 Org: User:

Start: 09/30/10 End: 06/30/12 Due: 06/30/13

MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis

Phase: N/A Priority: Normal

NCT ID: NCT02171104 Org: User:

Start: 07/10/14 End: 07/14/28 Due: 07/14/29

Biomarkers of Exposure and Effect in Standardized Research E-cigarette (SREC) Users

Phase: N/A Priority: Normal

NCT ID: NCT04003805 Org: User:

Start: 05/11/22 End: 01/20/26 Due: 01/20/27

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
A Study of FMT in Patients With AML Allo HSCT in Recipients	NCT03678493	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2019-09-09	2023-12-04	2024-12-04	-	-	2025-07-14
Stem Cell Transplant for Immunologic or Histiocytic Disorders	NCT00176865	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2002-08-31	2014-08-31	2015-08-31	-	-	2025-07-14
EMR Chemotoxicity Risk Calculator To Decrease Chemotherapy Toxicity	NCT05809557	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2023-01-09	2024-01-09	2025-01-09	-	-	2025-07-14
Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy	NCT01601548	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2012-07-31	2013-07-31	2014-07-31	-	-	2025-07-14
Clinical Trial of Two Study Drinks in Detoxification of Environmental Toxicants and Carcinogens	NCT03978117	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2021-02-18	2024-11-13	2025-11-13	-	-	2025-07-14
Stem Cell Transplantation for Hurler	NCT00176917	Masonic Cancer Center, University of Minnesota	user2@example.com	None	1999-05-31	2010-05-31	2011-05-31	-	-	2025-07-14
Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS	NCT03417154	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2018-08-13	2022-01-25	2023-01-25	-	-	2025-07-14
Early Diagnosis Of Childhood Cerebral ALD	NCT02948062	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2018-11-30	2023-07-31	2024-07-31	-	-	2025-07-14
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant	NCT00725062	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2008-06-30	2010-04-30	2011-04-30	-	-	2025-07-14
Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia	NCT00167167	Masonic Cancer Center, University of Minnesota	user2@example.com	None	1995-12-31	2006-01-31	2007-01-31	-	-	2025-07-14
High Dose Chemotherapy and Autologous Transplant for Neuroblastoma	NCT01526603	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2012-03-28	2023-05-30	2024-05-30	-	-	2025-07-14
Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis	NCT00618540	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2007-01-31	2013-05-31	2014-05-31	-	-	2025-07-14
Allo HSCT Using RIC for Hematological Diseases	NCT02661035	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2017-03-09	2023-05-29	2024-05-29	-	-	2025-07-14
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer	NCT00748163	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2008-08-31	2008-08-31	2009-08-31	-	-	2025-07-14
Biomarker Feedback for Smoking Cessation	NCT02206971	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2012-05-31	2014-12-31	2015-12-31	-	-	2025-07-14
Gut Microbiota in Intestinal Barrier Damage in Acute Leukemia Patients Undergoing Inpatient Induction	NCT03316456	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2017-08-22	2019-04-01	2020-04-01	-	-	2025-07-14
MT2017-45: CAR-T Cell Therapy for Heme Malignancies	NCT03642626	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2018-12-18	2028-06-01	2029-06-01	-	-	2025-07-14
Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa	NCT00478244	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2007-04-30	2011-08-31	2012-08-31	-	-	2025-07-14
Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca	NCT00784524	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2008-09-30	2014-07-31	2015-07-31	-	-	2025-07-14
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia	NCT00882206	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2009-04-30	2013-01-31	2014-01-31	-	-	2025-07-14
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL	NCT03019666	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2017-10-18	2022-08-15	2023-08-15	-	-	2025-07-14
Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)	NCT05705700	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2023-02-28	2030-01-31	2031-01-31	-	-	2025-07-14
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor	NCT01171469	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2010-09-30	2012-06-30	2013-06-30	-	-	2025-07-14
MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis	NCT02171104	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2014-07-10	2028-07-14	2029-07-14	-	-	2025-07-14
Biomarkers of Exposure and Effect in Standardized Research E-cigarette (SREC) Users	NCT04003805	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2022-05-11	2026-01-20	2027-01-20	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance